About factor viii inhibitor bypassing activity
Activated prothrombin complex concentrate
Used for
- Controls or prevents bleeding in hemophilia A or B with inhibitors
- Prevents bleeding during surgery in hemophilia with inhibitors
Usual adult dose
Usually 50–100 units/kg intravenously every 6–12 hours; maximum 200 units/kg daily. Dose depends on bleeding and clinical response.
Usual dose in children
Similar weight-based dosing to adults; specialist-directed, with the same daily maximum.
Common side effects
- Headache, dizziness, or nausea
- Allergic reactions, including rash or hives
- Blood clots, including heart attack or stroke
- Rarely, serious allergic reaction or abnormal red blood cell breakdown
Important warnings
- Use only under specialist supervision; monitor for blood clots and allergic reactions.
- Risk of clots may increase with high doses or concurrent emicizumab.
- Do not use in disseminated intravascular coagulation or acute thrombosis.
- Contains trace blood-derived proteins; infection transmission risk is very low.
Pregnancy
Use only when clearly needed; pregnancy safety information is limited. Hemophilia specialists should weigh benefits and risks.
Breastfeeding
Information is limited; use should be assessed by a clinician, considering the need for treatment.
Interactions
- Emicizumab: increased risk of blood clots and thrombotic microangiopathy; combination requires specialist oversight.
- Other clotting medicines may increase thrombosis risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.